In addition to targeting two different TAAs, one of BiTE antibodies can also target inhibitory immune checkpoints to overcome adaptive immune escape of tumor cells, mainly PD-L1, thus the SMITE pair was composed of CD3/TAA BiTE and CD28/PD-L1 BiTE [139]. Here, CD28 is linked to neoplasm.